Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Blind Spot in Post-Liver Transplant Care: Correlation and Causation in Immunosuppression, Drug Monitoring, and Immune Checkpoint Inhibitor-Related Rejection.

Health care science·2026
Same author

Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC.

Health care science·2026
Same author

Uptake of Shingles, Influenza, COVID-19 and Pneumococcal Vaccination in Patients with Inflammatory Arthritis: A Three-Centre Study.

Vaccines·2026
Same author

Readability of Self-Reported Measures in Psychosis.

The primary care companion for CNS disorders·2026
Same author

The mechanistic role of the thromboxane A2 receptor (TBXA2R) in non-small cell lung cancer (NSCLC).

Cancer cell international·2026
Same author

Epidemiology of unspecified degenerative nervous system disorders: mortality trends via CDC WONDER (1999-2025).

BMC neurology·2026

Related Experiment Video

Updated: Mar 19, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K

Targeting NK cell CLEC12B enhances cancer immunotherapy.

Peng Sun1,2,3, Xiaoyu Xu1,2,3, Bian Hu1,2,3

  • 1Department of Hepatobiliary Surgery, State Key Laboratory of Immune Response and Immunotherapy, Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, The First Affiliated Hospital of University of Science and Technology of China, University of Science and Technology of China, Hefei, China.

Nature Immunology
|March 18, 2026
PubMed
Summary

Natural killer (NK) cells are crucial for fighting cancer but are often suppressed in tumors. Researchers found CLEC12B inhibits NK cell activity, identifying a new target for cancer immunotherapy.

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K

Related Experiment Videos

Last Updated: Mar 19, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.2K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

2.0K

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Medicine

Background:

  • Natural killer (NK) cells are key innate immune cells with cytotoxic functions against tumors.
  • The tumor microenvironment often suppresses NK cell activity, hindering effective antitumor immunity.
  • Understanding NK cell dysfunction mechanisms is vital for developing novel cancer immunotherapies.

Purpose of the Study:

  • To identify molecular mechanisms responsible for NK cell dysfunction within the tumor microenvironment.
  • To investigate the role of C-type lectin receptor CLEC12B as an inhibitory checkpoint on NK cells.
  • To develop and evaluate a therapeutic strategy targeting the CLEC12B pathway for cancer treatment.

Main Methods:

  • Analysis of CLEC12B expression in tumor-infiltrating NK cells and correlation with clinical prognosis.
  • Identification of lipoprotein lipase as a functional ligand for CLEC12B.
  • Development of a high-affinity nanobody to disrupt the CLEC12B-lipoprotein lipase interaction.
  • Preclinical evaluation of the nanobody in tumor models, including combination with PD-1 blockade.

Main Results:

  • High CLEC12B expression in tumor-infiltrating NK cells is associated with poor prognosis in hepatocellular carcinoma.
  • Lipoprotein lipase binds to CLEC12B, initiating inhibitory signaling that impairs NK cell activation.
  • A novel nanobody targeting the CLEC12B-lipoprotein lipase axis revitalized NK cell activity and suppressed tumor growth in preclinical models.
  • The nanobody demonstrated synergistic efficacy with PD-1 blockade in preclinical cancer models.

Conclusions:

  • CLEC12B acts as an inhibitory checkpoint restricting NK cell-mediated antitumor immunity.
  • The CLEC12B-lipoprotein lipase axis represents a novel target for overcoming tumor-induced NK cell suppression.
  • A CLEC12B-targeting nanobody shows therapeutic potential for re-energizing NK cells against solid tumors, particularly in combination with existing immunotherapies like PD-1 blockade.